LENZ
$12.50
LENZ Therapeutics, Inc.
Intraday
Recent News
A Look At LENZ Therapeutics (LENZ) Valuation After VIZZ Launch Momentum And New Lunatus Agreement
LENZ Therapeutics (LENZ) has been getting attention after strong early use of its FDA approved presbyopia eye drop VIZZ and an exclusive commercialization deal with Lunatus covering several Middle East markets. See our latest analysis for LENZ Therapeutics. Those headlines sit alongside a mixed share price picture, with LENZ trading at $15.57 after a 1 day share price return of 4.71%, a 30 day share price return of 14.17% decline and a 1 year total shareholder return of 32.89% decline. This...
LENZ Therapeutics (LENZ) Is Down 7.1% After VIZZ Middle East Deal And Early Launch Data - Has The Bull Case Changed?
LENZ Therapeutics and Lunatus Marketing & Consulting FZCO recently announced an exclusive agreement for Lunatus to register and commercialize VIZZ, an FDA-approved aceclidine-based eye drop for presbyopia, across key Middle Eastern markets including the UAE, Saudi Arabia, and Qatar. This deal, alongside early US launch data showing around US$1.6 million in Q4 2025 VIZZ revenue and more than 20,000 prescriptions, highlights LENZ’s push to turn its presbyopia franchise into a global...
Analysts Expect Breakeven For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Before Long
LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) is possibly approaching a major achievement in its business, so we would like...
Lenz, Lunatus announce exclusive partnership for VIZZ in Middle East
LENZ Therapeutics (LENZ) announced an exclusive distribution agreement for Lunatus to register and commercialize VIZZ for the treatment of presbyopia in the Middle East Region. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. Lunatus is an independent pharmaceutical company specialized in the commercialization of pharmaceutical products in the Middle East. Under
Insider Spends US$239k Buying More Shares In LENZ Therapeutics
Potential LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders may wish to note that the Co-Founder & Director, James...